pMedGR builds upon an initial regional set of core partners that combine excellence in clinical and translational research (MedUoA) with expertise in high-end technologies for biomedical discovery (Fleming, BRFAA).

 

The Lead Partner and Coordinator is the Medical School of the National and Kapodistrian University of Athens (MedUoA). MedUoA is the largest and oldest Medical School in the country and already initiated in the context of the School’s strategic development plans the establishment of a Core Bioresearch facility and a Center of Excellence in Personalised Medicine. The School employs 650 faculty and 4000 medical students of outstanding quality which provide a very significant regional asset and critical mass for further development in the proposed area. The School is connected to several excellent teaching hospitals in the area, offering a unique opportunity to exploit the knowledge triangle (education, research, innovation) towards creating the next generation of researchers and clinicians that will develop and implement personalized medicine applications. Furthermore, MedUoA already has (and will further develop) a vast array of clinical data and biological specimens, which will serve as the basis for patient stratification approaches, biomarker identification and companion diagnostics development.

 

MedUoA has formed strategic partnerships with the top biomedical research centers: the Biomedical Sciences Research Center “Alexander Fleming” (Fleming), and the Biomedical Research Foundation of the Academy of Athens (BRFAA). These institutes have proven scientific excellence in high-end biomedical technologies and have gained extensive visibility in the European Research Area and internationally through state of the art research and innovation programs in basic, as well as translational and applied science in biology, biomedicine and biotechnology. In addition, these Research Centers are leading the development of additional national, large-scale research infrastructures (INFRAFRONTIER, ELIXIR, BBMRI and others).

 

Additional academic and industrial partners may be added at later stages, to complement the Node’s technological platforms and expand its clinical areas of expertise.

 

pMedGR acts as a smart specialization regional “meta-structure” bringing together intersectoral partners, including:

 

• Pharmaceutical R&D departments that wish to include patient stratification approaches and biomarker development along with their drug development pipelines.

 

• Biotechnology SMEs and diagnostics developers that wish to co-develop companion diagnostics for personalised medicines.

 

 

• Biomedical and clinical researchers, who wish to perform proof of concept studies and translate their findings in clinical applications for personalised medicine (including patient stratification, biomarker discovery etc).

 

 

• National and European biomedical research infrastructures, resources and programs, providing high-end services along the drug development pipeline (including the Core Bioresearch facility at MedUoA, ESFRI infrastructures, IMI projects etc).

 

 

• Patients and patient foundations, that wish to accelerate the development of new therapeutics and theranostics, and push innovative treatments to the clinic and the market faster.

 

• Policy-makers that wish to maximize socio-economic benefits through public-private partnerships and ensure the sound management and allocation of public funds in the interest of both industry and society.